DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
193	プラダー・ウィリ症候群	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03649477 (ClinicalTrials.gov)	November 20, 2018	24/8/2018	Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome	Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)	Prader-Willi Syndrome	Drug: intranasal carbetocin Dose 1;Drug: intranasal carbetocin Dose 2;Drug: placebo	Levo Therapeutics, Inc.	NULL	Active, not recruiting	7 Years	18 Years	All	130	Phase 3	United States;Australia;Canada

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03649477
(ClinicalTrials.gov)

November 20, 2018

24/8/2018

Phase 3 Study of Intranasal Carbetocin (LV-101) in Patients With Prader-Willi Syndrome

Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) With Long Term Follow-Up (CARE-PWS)

Prader-Willi Syndrome

Drug: intranasal carbetocin Dose 1;Drug: intranasal carbetocin Dose 2;Drug: placebo

Levo Therapeutics, Inc.

NULL

Active, not recruiting

7 Years

18 Years

All

130

Phase 3

United States;Australia;Canada